IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise in slowing kidney disease
Disease control OngoingThis study tests a new medicine called sparsentan for people with IgA nephropathy, a kidney disease that can lead to kidney failure. About 400 adults with the condition took either sparsentan or a standard blood pressure drug for about 2 years. The goal was to see if sparsentan c…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New drug aims to slow kidney damage in IgA nephropathy patients
Disease control OngoingThis study tests an investigational drug called povetacicept in about 605 adults with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and preserve kidney function better than a placebo. Participants must have a confirmed diagnosis and s…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC